Fig. 1

Characteristics of circRAD23B in ovarian cancer. (A) The schematic diagram of circRAD23B (hsa-circ-0087855) arose from exon 2,3,4 of the RAD23B gene. The sequence of hsa-circ-0087855 in circBase was consistent with the result of Sanger sequencing. (B) The expression level of circRAD23B in different ovarian cancer cells. (C) The RNA level of circRAD23B and RAD23B was examed at four time pionts after the treament of Actinomycin D in HO8910 and A2780 cell lines. (D) The divergent primers detected circRAD23B in cDNA but not in gDNA, GAPDH was used as a negative control. (E) The stability of circRAD23B was not affected by RNase R in HO8910 and A2780 cell lines. (F) Immunofluorescence assay showed that circRAD23B was localized in the cytoplasm. (G) RNA nucleoplasmic separation assay showed that circRAD23B was mainly distributed in the cytoplasm, and U6 and GAPDH were used as positive controls for the nucleus and cytoplasm, respectively. (H) Relative expression of circRAD23B in carboplatin-sensitive and -resistant patients. (I) The overall survival analysis in patients with different circRAD23B level. (J) Nomogram containing common clinicopathological factors and circRAD23B expression in ovarian cancer patients. Graph represents mean ± SD; *p < 0.05, and ***p < 0.001